Recent Updates — VTGN

Vistagen Therapeutics implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate capabilities required for U.S. registration-directed Phase 3 development of fasedienol, its lead candidate for social anxiety disorder. The company estimates it will incur severance and termination costs of approximately $1.0 million. This restructuring is intended to reduce operating expenses, preserve capital with cost efficiencies, and align the workforce size with late clinical-stage priorities, expected to save approximately $3.2 million in salary and benefits annually. Vistagen Therapeutics operates as a clinical-stage biopharmaceutical company developing treatments for psychiatric disorders.

The Board of Directors approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, effective October 7, 2026. The revised plan expands eligibility for involuntary termination benefits beyond transactions involving a Change in Control, allowing Eligible Employees to receive lump-sum cash payments based on monthly base salary and COBRA premiums following terminations without Cause or for Good Reason. All current executive officers are considered Eligible Employees under the updated terms. Vistagen Therapeutics is a clinical-stage biopharmaceutical company developing therapies for neurological disorders.

Vistagen Therapeutics announced preliminary positive data from the open-label extension (OLE) of its PALISADE-4 Phase 3 study evaluating fasedienol for social anxiety disorder. The safety population included 322 subjects who used the nasal spray as needed up to six times daily for up to 12 months. Treatment was well-tolerated with no new drug-related safety findings and a discontinuation rate due to adverse events of only 1.6%. Exploratory efficacy data over four months showed clinically relevant improvements on both clinician-administered (LSAS) and patient-reported (SPIN) scales, with LSAS scores improving by up to 31.4 points at Month 4. The company plans to meet with the FDA in the current quarter regarding a potential New Drug Application for fasedienol. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company developing intranasal neurocircuitry-focused product candidates.

Vistagen Therapeutics reported fiscal year 2027 first quarter results ending June 30, 2026. The company recognized $1.48 million in revenue due to the expiration of an exclusivity period under its agreement with Fuji Pharma. Operating expenses totaled $14.8 million, comprising $10.9 million in research and development costs and $3.9 million in general and administrative expenses, resulting in a net loss of $13.0 million compared to $15.1 million in the prior year period. Cash, cash equivalents, and marketable securities stood at $31.7 million as of June 30, 2026. Clinically, Vistagen announced preliminary data from the open-label extension of PALISADE-3 for fasedienol and post-hoc data from Phase 3 study PALISADE-4 showing nominally statistically significant improvement in a subpopulation with very severe social anxiety disorder. The company plans to engage with the FDA regarding the future Phase 3 path for fasedienol and received an FDA 'Study May Proceed' letter for refisolone. Additionally, Vistagen appointed Angel S. Angelov as Chief Medical Officer and Douglas J. Williamson to its Board of Directors. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company developing rapid-onset intranasal product candidates called pherines.